FDA Brief

Warning letters Drugs

FDA warning letter to

Lovelace Biomedical Research Institute

MediumIssued Oct 6Posted Oct 13Center for Drug Evaluation and Research (CDER)

Lovelace Biomedical's quality unit failed to ensure final drug study reports matched raw data, FDA says.

What happened

FDA inspected Lovelace Biomedical Research Institute from April 7 to 18, 2025, under its Bioresearch Monitoring Program for nonclinical laboratory studies. FDA found that the quality assurance unit (QAU) did not review final study reports to ensure reported results accurately reflected raw data: final reports omitted abnormal cageside observations and dosing issues from two protocols. Lovelace responded May 9, 2025, and submitted revised reports dated May 30, 2025, but FDA said the response lacked sufficient detail on updated procedures, training, and audits.

What FDA found

  1. The quality assurance unit (QAU) failed to review the final study report to ensure reported results accurately reflected raw data.

    21 CFR 58.35(b)(6)
  2. For one protocol, the final report omitted abnormal cageside clinical observations for 20 of 34 animals, including sneezing, runny or bloody nose, abnormal stool, sunken eyes, bloating, hunched posture, low appetite, and heavy breathing.

    21 CFR 58.35(b)(6)
  3. For the same protocol, the final report omitted dosing issues: an animal lay on the cage bottom for one hour and ten minutes after infusion, two animals pulled out venous catheters during test article infusion, two pulled out catheters during control article infusion, and one had test article infiltration into surrounding tissue.

    21 CFR 58.35(b)(6)
  4. For the second protocol, the final report omitted abnormal cageside observations for all 48 animals, including bloody or dark-red, liquid, loose, mucoid, or unformed stools.

    21 CFR 58.35(b)(6)
  5. For the second protocol, the final report omitted dosing issues: irregular breathing during aerosol dosing and one animal not dosed due to a swollen muzzle.

    21 CFR 58.35(b)(6)
  6. FDA found the corrective action plan lacked sufficient details on updated SOPs, training, and planned audits.

What FDA wants

FDA asks the company to notify the office in writing within 15 business days of receipt of the letter of actions taken to prevent similar violations. If Lovelace believes it complied, it should include its reasoning and supporting information.

Who should pay attention

  • sponsors relying on Lovelace's nonclinical study data
  • contract research organizations and testing facilities
  • drug developers submitting nonclinical reports to FDA

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Pritam International Private Limited

    Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.

    High risk
  3. Conroe Welding Supply, Inc.

    FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).

    High risk
  4. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk